Publications
Original, peer-reviewed articles:
1. Crown J, Kritz A, Vahdat L, Reich L, Moore M, Hamilton N, Schneider J, Harrison M, Motzer R, Gilewski T, Hudis C, Gulati S, Norton L: Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy. J Clin Oncol 11:1144-1149,1993
2. Crown J, Vahdat L, Fennelly D, Kritz A, Norton L: High-dose chemotherapy with hematopoietic support. Ann NY Acad Sci 698:378-388, 1993
3. Vahdat L, Wong E, Wile MJ, Rosenblum M, Foley K, Warrell RP Jr: Therapeutic and neurotoxic effect of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood 84:3429-3434, 1994
4. Vahdat L, Eardley A, Maslak P, Heller G, Scheinberg D, Warrell RP Jr.: Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PML/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 84:3843-3849, 1994
5. Vahdat L, Raptis G, Fennelly D, Reich L, Harrison M, Tiersten A, Norton L, Crown JPA: Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer. Clin Cancer Research 1:1267-1273, 1995
6. Vahdat L, Raptis G, Fennelly D, Crown J: High dose chemotherapy of metastatic breast cancer. Cancer Invest 1995;13(5):505-10
7. Crown J, Raptis G, Hamilton N, Fennelly D, Vahdat L, Norton L: High-dose chemotherapy of breast cancer: current status and developmental strategies. Eur J Cancer 1995;31(5):809-11
8. Ross AA, Layton TJ, Ostrander AB, Passos-Coelho JL, Davis JM, Huelskamp AM, Noga SJ, Davidson NE, Kennedy MJ, Cooper BW, Gerson SL, Lazarus HM, HollandK, Gluck S, Moss TJ, Kaubish A, Vahdat L, Antman K, Comparative analysis of breast cancer contamination in mobilized and nonmobilized hematopoietic grafts.Journal of Hematotherapy 1996 Oct;5(5):549-52
9 Garrett TJ, Vahdat L, Kinne D: Systemic adjuvant therapy of breast cancer. J Surg Oncol 1997, 64:167-172
10. Papadopoulos KP, Ayello J, Tugulea S, Heitjan DF, Williams C, Reiss R, Vahdat LT, Suciu-Foca N, Antman KH and Hesdorffer CS. Harvest quality and factors affecting collection and engraftment of progenitor CD34 cells in patients with breast cancer scheduled for high dose CTCb with chemotherapy and G-CSF mobilized peripheral blood progenitor cell support. J Hematotherapy 1997; 6: 61-68
11.Hesdorffer C, Ayello J, Ward M, Kaubisch A, Vahdat L, Balmaceda C, Garrett T, Fetell M, Reiss R, Bank A, Antman K. A Phase I trial of retroviral-mediated transfer of the human MDR-1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem cell transplantation. J Clin Oncol 16:165-172, 1998
12. Vahdat LT, Papadopolous K, Balmaceda C, Fung B, Garrett TJ, Savage D, Tiersten A, Heitjen D, McGovern T, Dunleavy J, Kaufmen L, Antman KH, Hesdorffer C. Phase I trial of sequential high dose chemotherapy with escalating dose paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Clin Cancer Research 4:1689-1695, 1998
13. Papadopoulos KP, Garvin JH, Fetell M, Vahdat LT, Garrett TJ, Savage DG, Balmaceda C, Bruce J, Sisti M, Isaacson S, De LaPaz R, Hawks R, Bagiella E, Antman KH, Hesdorffer CS. High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults. Bone Marrow Transplantation 22:661-667, 1998
14. Lee RP, Oster MW, Balmaceda C, Hesdorffer CS, Vahdat LT, Papadopoulos KP. Bilateral facial nerve palsy secondary to the administration of high-dose paclitaxel.
Ann Oncology 10: 1245-1247, 1999
15. Papadopoulos KP, Balmaceda C, Fetell M, Kaufman E, Vahdat LT, Bruce J, Sisti
M, Isaacson S, De LaPaz R, Savage D, Troxel A, Antman KH, Hesdorffer CS. A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with
hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumors. J of Neuro-Oncology 44:155-162, 1999
16. Papadopoulos KP, Egorin, MJ, Huang M, Troxel AB, Kaufman E, Balmaceda CM, Vahdat LT, Hesdorffer CH. The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. Cancer Chemother Pharmacol 47: 45-50, 2001
17. Vahdat L, Papadopoulos K, Lange D, Leuin S, Rosenman S Kaufman E, Donovan D, Frederick D, Bagiella E, Tiersten A, Nichols G, Garrett T, Savage D , Antman K, Hesdorffer C, Balmaceda C. Reduction of Paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Research 7: 1192-1197, 2001
18. Jacobson JS, Troxel AB, Evans, J, Klaus L, Vahdat L, Kinne D, Lo S, Moore A, Rosenman P, Kaufman EL, Neugut AI, Grann VR. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer.
J Clin Oncol 19(10): 2739-45, 2001
19. Vahdat LT, Balmaceda C, Papadopoulos K, Frederick D , Donovan D, Sharpe E, Kaufman E, Savage D, Tiersten A, Nichols G, Haythe J, Troxel A, Antman K, Hesdorffer C. Phase II trial of sequential high dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Bone Marrow Transplantation 30: 149-155, 2002
20. Nichols G, de Castro K, Wei L-X, Griffin M, Oratzi A, Murty VVVS, Troxel A, Vahdat L, Hesdorffer CS. Therapy-related myelodysplastic syndrome after autologous stem cell transplantation for breast cancer. Leukemia Sept;16(9):1673-9, 2002
21. Tiersten A, Nelson C, Talbot S, Vahdat L, Fine R, Brafman L, Shriberg L, Antman K and Petrylak DP. A phase II trial of docetaxel and estramustine phosphate in refractory metastatic breast cancer. Cancer Feb 97 (3): 537-544,2003
22. Savarese D, Savy G, Vahdat LT, Wischmeyer, Corey B.Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treatment Reviews, Dec;29(6): 501-13, 2003
23. Clark A, Vahdat LT. Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome (PPE): etiology and emerging therapies. Supportive Cancer Therapy, July 1 (4): 213-218, 2004
24. Ocean A, Vahdat LT. Chemotherapy-induced peripheral neuropathy: Etiology and emerging therapies. Supportive Care in Cancer, September 12 (9): 619-625, 2004
25. Skerret D, Mansukhani M, Moore EM, Bernstein DS, Vahdat L. Cytokine genotype polymorphisms: associations with primary breast carcinomas in women. Cancer Investigation 23:208-214, 2005
26. Stubblefield MD, Vahdat LT, Balmaceda CM, Troxel A, Hesdorffer CS, Gooch CL. Glutamine as a neuroprotective agent in high dose paclitaxel-induced peripheral neuropathy: A clinical and electrophysiologic study. Clinical Oncology 17:271-276, 2005
27. Papadopoulos KP, Noguera-Irizarry W, Wiebe L, Hesdorffer DS, Garvin J, Nichols GL, Vahdat LT, Skerrett D, Bernstein D, Sharpe E, Savage DG. Pilot study of tandem high dose chemotherapy and autologous stem cell transplantation with a novel combination of regimens in patients with poor risk lymphoma. Bone Marrow Transplant Sep;36(6)491-7, 2005
28. Herbst R, Bajorin DF, Bleiber H, Blum D, Hao D, Johnson BE, Ozols RF, Demetri GD, Ganz PA, Kris MG, Levin B, Markman M, Raghavan D, Reaman GH, Sawaya R, Schucter LM, Sweetenham JW, Vahdat LT, Vokes E, Winn RJ, Mayer RJ, American Society of Clinical Oncology. Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention and screening—a report from the American Society of Clinical Oncology. J Clin Oncol Jan 1:24(1): 190-205, 2006
29. Tiersten A, Selleck M, Smith DH, Wertheim I, Kaufman E, Hershman D, Vahdat L, Savage DG, MacArthur RB, Hesdorffer, C. Phase I/II study of tandem cycles of high dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer. Int J Gynecol Cancer Jan-Feb;16(1):57-64, 2006
30. Sparano JA, Moulder S, Kazi A, Vahdat L, Li T, Pellegrino C, Blaskovich M, Munster P, Lee P, Hoschander S, Hopkins U, Hershman D, Wright JJ, and Sebti, S.. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I-II trial incorporating tipifarnib plus dose-dense doxorubicin and cyclophosphamide. J Clin Oncol; 24 (19): 3013-8, 2006
31. Oktay K, Oktem O, Reh A, Vahdat L. Measuring the impact of chemotherapy on fertility in women with breast cancer. J Clin Oncol 24(24):4044-6, 2006
32. Conlin AK, Vahdat L. Dermatologic toxicity of ixabepilone. Anticancer Res 26(3B) 2279-80, 2006
33. Huston TL, Pressman PI, Moore An, Vahdat L, Hoda SA, Kato M, Weinstein D, Tousimis E. The presentation of contralateral axillary lymph node metastases from breast carcinoma: a clinical management dilemma. Breast J 2007 Mar-Apr;13(2): 158-64
34. Vahdat LT, Fine R, Dinnen R, Do T, Weintreb T, Petrylak DP. Lack of effect of glutamine on taxane cytotoxicity in cancer cell lines. (manuscript submitted)
35. Vahdat LT, Cohen D, Zipin D, Lo KS, Donovan D, Sharpe D, Savage D, Tiersten A, Nichols G, Troxel A, Hesdorffer CS. Randomized trial of low dose interleukin 2 vs cyclosporine A and interferon γ after high dose chemotherapy with peripheral blood progenitor support in women with high risk primary breast cancer. Bone Marrow Transplantation e pub ahead of print June 11 2007
36. Naik R, Jin D, Chuang E, Gold E, Tousimis E, Christos P, de Dalmas T, Donovan D, Rafii S, Vahdat L. Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. Breast Cancer Treat Feb 15 on-line 2007
37. Roche H, Yelle L, Cognetti F, Mauriac L, Bunnell C, Sparano J, Kerbrat P, Delord JP, Vahdat L, Peck R, Lebwohl D, Ezzeddine R, Cure H. Phase II clinical trial of ixabepilone (BMS 247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol epub ahead of print July 2 2007
38. Thomas E, Tabernero JM, Fornier M, Conte P, Fumoleau P, Lluch A, Vahdat LT, Bunnell CA, Burris HA, Viens P, Peck R, Martin M. Phase II clinical trial of ixabepilone (BMS 247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol epub ahead of print July 2 2007
39. Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, viens P Cai C, Mullaney B, Peck R, Hortobagyi GN. Efficacy and safety of ixabepilone ( BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol epub ahead of print July 2 2007
40. Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ Eisenberg BL, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Reaman GH, Sawaya R, Schilsky RL, Schuchter LM, Sweetenham JW, Vahdat LT, Winn RJ: American Society of Clinical Oncology. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. J Clin Oncol 25(1) 146-62, 2007
41. Jhaveri K, Halperin P, Shin S, Vahdat L. Erythema nodosum secondary to aromatase inhibitor use in breast cancer: case reports and review of the literature. (Manuscript accepted Breast Cancer Research and treatment 2007)
42. Taylor C, Hershman D, Pegram M, Petrylak D, Taub R, Vahdat L, Cheng B Knutson K Clynes R. Treatment with trastuzumab induces anti-Her2 humoral immunity. (Manuscript accepted in Clinical Cancer Research 2007)
43. Loizzo J, Peterson J, Wolf E, Altemis M, Briggs W, Vahdat L, Charlson M. The Effect of a contemplative self-healing program on quality of life in women with breast cancer and other gynecologic cancers. (Manuscript submitted)
44. Vahdat L. Ixabepilone: A novel anti-neoplastic agent with low susceptibility to multiple tumor resistance mechanisms. (Manuscript submitted)
Invited manuscripts:
1. Fennelly D, Vahdat L, Schneider J, Hakes T, Raptis G, Wasserheit C, Kritz A, Gulati S, Norton L: High intensity therapy with peripheral blood progenitor cell support. Sem Oncol 1994; 21:21-25
2. Vahdat L, Antman KH: High dose therapy for breast cancer. Blood Reviews 1995, 9:191-200
3. Vahdat L, Antman KH. Hematopoietic Stem Cell Transplantation for breast cancer. Current Opinion in Hematology 1997, 4:381-389
4. Vahdat L, Antman KH: High dose chemotherapy for breast cancer. Clinical Oncology Updates 1999, 2: No. 3.
5. Mones J, Vahdat L: Basaloid Breast Cancer and response to therapy: review of the literature and future directions. Clinical Breast Cancer 2007
Reviews and educationally relevant publications:
Editorial and Critical Reviews
1. Vahdat L. Antman KH. Breast Diseases: A Year Book Quarterly 6(1), 1995
2. Vahdat L. Breast Diseases: A Year Book Quarterly 6(2), 1995
3. Atieh D and Vahdat L. Microtubule stabilizing agents: halichondrin B analog (E 7389) in Breast Diseases: A Year Book Quarterly 18(1)21-23, 2007
Textbook Chapters:
1. Vahdat L, Antman KH. Dose-intensive therapy in breast cancer. In: Antman KH, Armitage JA, eds. High-dose cancer therapy: pharmacology, hematopoietins and stem cells. Baltimore, MD, Williams and Wilkins, 1995, pp. 802-82
2. Vahdat LT, Tiersten A, Antman KH. Autologous hematopoietic stem cell transplantation for breast cancer. In: Atkinson K, ed. Clinical bone marrow and stem cell transplantation. Cambridge, UK, Cambridge University Press, 2nd Edition. 2000, pp. 317-335
3. Vahdat L, Antman KH. Dose-intensive therapy in breast cancer. In: Antman KH, Armitage JA, eds. High-dose cancer therapy: pharmacology, hematopoietins and stem cells. Philadelphia, PA, Lippincott Williams and Wilkins, 2000, pp. 821-840
4. Siegel A, Vahdat L. Allogeneic stem cell transplant for Breast Cancer. In: Lazarus HM, Laughlin MJ, In eds. Allogeneic Stem Cell Transplantation. Totowa, NJ, Humana Press 2003, pp.57-68
5. Atieh, DM, Vahdat LT. Targeted therapy in breast cancer. In Teicher B ed. Molecular Targeting in Oncology. Totowa, NJ, Humana Press. 2007
